EMA Authorised: Rimmyrah (ranibizumab) — Qilu Pharma Spain S.L.

View source ↗

Summary

The EMA authorises Rimmyrah (ranibizumab) by Qilu Pharma Spain S.L. for multiple ophthalmic indications including wet age-related macular degeneration and macul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Degenerative Myopia
• Diabetes Complications
• Macular Edema
• Wet Age-related Macular Degeneration

Drugs mentioned

• Rimmyrah (ranibizumab)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization. MAH: Qilu Pharma Spain S.L.. Decision date: 15/06/2026